This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Gene Merutka, PhD
Head of Chemistry, Manufacturing & Controls at Sapience Therapeutics


Gene Merutka is the Vice President of Chemistry, Manufacturing and Controls (CMC) at Sapience Therapeutics. Dr. Merutka has over 25 years of experience in the biopharmaceutical industry and specializes in the development of peptide therapeutics, including CMC, preclinical, quality and regulatory CMC. Prior to his role with Sapience, Dr. Merutka co-founded and served as Vice President and Head of Non-Clinical Development and CMC at Merganser Biotech, Inc., which was developing a Hepcidin mimetic to treat iron storage diseases. Previously, he served as the Head of CMC Development and Vice President at Azelon Pharmaceuticals, Inc. (alternate name Zelos Therapeutics Inc.), where he focused on novel formulations and delivery routes for parathyroid hormone (PTH 1-34). He also worked at Vicuron Pharmaceuticals, where he was responsible for product development and played an important role in the submission of two approved NDA filings, and at Trimeris Inc., where he was part of the team that developed Fuzeon (Enfuvirtide).

Agenda Sessions

  • Peptide Development Strategies from Discovery to NDA


Speakers at this event